BioPortfolio Logo 

BioPortfolio Bulletin

www.bioportfolio.com 

  http://www.bioportfolio.co.uk/bulletin_38.htm                          May 11th 2004

Lead Sponsor:
 

   Biotech industry expert Dr. Ron Garren analyzes newsworthy events in the medical marketplace and places them in the context of value to the investor. Through his website, he distributes frequent email alerts to subscribers. An archive of past alerts, along with a model portfolio of biotech stocks is also available.

http://www.biotechinsight.com/
In this WEEK's issue we are concentrating on PAIN:
1) Growthink Research's 2004 Healthcare Venture Capital Report 
2) Emerging Neuropathic Pain Therapeutics
3) Rheumatoid Arthritis 
4) Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities
5) Intelligence and information resources on Pain
6) BioWatch - email news alerts on the life science industry

Headline Sponsor: 		  BIOPHARM EXCHANGE #7 AUCTION. Major Sale of Biotechnology, Pharmaceutical and Lab Equipment.  Bid online May 25, 6am to 2pm PT, at DoveBid’s website: www.dovebid.com.  Assets located in California and North Carolina.  For more information, visit our website or call 800-665-1042.
Growthink Research's 2004 Healthcare Venture Capital Report 
Growthink Research’s 2004 Healthcare Venture Capital Report analyzes and profiles the 470 healthcare companies that raised venture capital in 2003 (representing $5.8 billion) and more than 525 investors that funded them. All company and investor profiles include complete contact information.  The report is organized by 4 key sectors:· Biotechnology/Pharmaceutical | Diagnostic/Patient Care | Healthcare Software & Services | Medical Devices.  Pages: 213. Format: PDF Published: 24th April 2004

The Report provides many benefits to several audiences:

  • Early Stage Ventures: unique insight into the funding market; identification of the best investors to target; identification of potential partners; critical competitive intelligence.
  • Venture Capitalists: critical competitive intelligence for decision-making regarding current portfolio and new investments.
  • Mid-Stage and Late-Stage/Fortune 500 Companies: critical competitive intelligence and identification of potential ventures to invest in, partner with, or acquire.
  • Product & Service Providers: identification of the most promising ventures that could use your products and services.

http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_Growthink_5.html 

 

Emerging Neuropathic Pain Therapeutics
Emerging Neuropathic Pain Therapeutics Currently, neuropathic pain is managed through a combination of anticonvulsants, opioids, and various antidepressants. Yet, most therapeutics available on the market are not specifically indicated for neuropathic pain, and exhibit inadequate efficacy and adverse events profile. Therefore, many pharmaceutical companies recognize the opportunity to provide better therapeutics and the subsequent market potential. With promising clinical trial results, eleven emerging therapeutics will likely gain significant market share between 2004 and 2009. 161 pp. January 2004.

Price: $3,200.00 Order online:
http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html 

 

Rheumatoid Arthritis 
Emerging Neuropathic Pain Therapeutics With the worldwide prevalence of rheumatoid arthritis (RA) estimated at more than 20 million people in 2004 (based on U.S. Census Bureau data, World Health Organization statistics, and epidemiology studies), there is increasing demand for effective therapeutics to improve patient quality of life. At present, there is no cure for RA. Historically, the goal of treatment has been to provide pain relief, and slow disease progression. Patients with joint pain usually try over-the-counter (OTC) painkillers and visit the doctor only when the pain continues. The first line of treatment for RA is the use of traditional analgesics while corticosteroids are very effective in reducing inflammation. Second line treatments include disease-modifying anti-rheumatoid drugs (DMARDs), such as methotrexate and biological response modifiers are prescribed for patients experiencing severe RA symptoms who have not responded to DMARDs. Because multiple classes of medications are available, it is routine for physicians to make several attempts before finding the appropriate treatment regimen for each patient. Eight emerging therapeutics are forecasted to enter this segment between 2004 and 2009. 235 pp. March 2004

Price: $3,200.00 Order online:
http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html 

 

Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities
Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities Cancer pain can be associated with the cancer itself or with conventional cancer treatments such as chemotherapy or surgery, and it affects over 3 million people in the US alone. Currently, there is a vast range of drugs used in the treatment of cancer pain including opioids, NSAIDs, antidepressants and anticonvulsants, yet most physicians consider morphine to be the current gold standard.
  • Key data and detailed analysis of the 7 leading pharmaceutical markets: the US, Japan, Germany, France, Italy, Spain, and the UK
  • In-depth analysis of presentation rates, diagnosis and referral patterns of cancer pain
  • Detailed examination of first, second and third line therapies for the treatment of mild, moderate and severe cancer pain
  • Investigation of the treatment of breakthrough pain

Report Highlights

Cancer pain affects over three million people in the US alone, yet despite the availability of a wide range of analgesics and published treatment guidelines, many patients still receive inadequate pain management

Increased education and awareness of cancer pain and its management among physicians and patients is of critical importance in improving treatment outcomes

Reasons to Purchase

  • Identify commercial opportunities from an understanding of the prevalence of cancer pain in the seven major pharmaceutical markets
  • Exploit the opportunity to play a pivotal role in promoting effective pain management by providing increased patient and physician education
  • Identify first, second and third-line preferred therapies for cancer pain, and the novel non-invasive formulations of breakthrough pain analgesics.

Price $12,800.00 Order online:  http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a268 

 

Intelligence and knowledge resources supporting Pain R&D
BioPortfolio offers its readers the opportunity to access a wide range of information resources on CNS diseases - to evaluate review the links below:

1) Pain R&D News: Back Pain | Pain | Palliative Care Pain | Arthritis Rheumatoid

2) Pre-defined web searches covering all Pain conditions: Pain | Palliative Care Pain | Back Pain

3) Therapeutic Advances - Focus on Pain:
http://www.bioportfolio.com/LeadDiscovery/targetpain.htm

4) Subscribe to CNS Diseases DailyUpdate:
http://www.bioportfolio.com/leaddiscovery/daily_update_index.htm

5) Leading CNS Diseases Companies - Stock prices
http://www.bioportfolio.com/nasdaq/scroll_Neurological.htm 

 

BioWatch - email news alerts on the life science industry

You select the topic and we deliver breaking news direct to your email box!

“Sentrx has been a subscriber to BioPortfolio for more than a year and we are very pleased with the services provided. We receive news items throughout the day to identify companies that may have a need for Sentrx drug safety solutions. Using this information, we have established a direct mail campaign that is proving to be successful at generating leads. All of our press releases are distributed through BioPortfolio, and the service reaches a wide audience at a reasonable price. Any technical issues are quickly resolved in a courteous, professional manner. I highly recommend BioPortfolio.com.” Jill M. Notte, Director of Marketing, Sentrx 

"We have used the BioPortfolio BioWatch News email alert service for two years to track commercial developments in diabetes, oncology and CNS – we will be subscribing for a third year because we find it a user friendly and an excellent vehicle for keeping us aware”. Lester Salans.

Download the BioWatch News Email Alert pdf brochure (100 Kb) (100 Kb) and order form!

Read more at: http://www.bioportfolio.com/news_tracking/index.htm 

Contact us:
Editorial and features: peter.barfoot@bioportfolio.com 

Subscriber information:
To subscribe for the BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com

To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com WITH NO SUBJECT.  The system will automatically remove your email address from the list based on your email address.  If your email has changed please email peter.barfoot@bioportfolio.com with a list of your email address and we will manually unsubscribe for you.  Thank you for your understanding.

©2004 BioPortfolio Limited